WeVote
Log In

Bill

Bill

AB 234

Relating to: the electronic vaping device directory and electronic nicotine devices. (FE)

2025-2026 Regular Session Introduced by Tony Kurtz and 1 co-sponsor

Nevada Medicaid will cover screening for lung, colorectal, and prostate cancers to improve early detection among enrollees.

Failed to concur in pursuant to Senate Joint Resolution 1
0
WeVote Research Nonpartisan
Bill Summary · AB 234

AB 234 — Medicaid coverage for screening for certain forms of cancer (BDR 38‑893)

Status: Enacted (Chaptered 2025). Introduced Jan–Feb 2025; Governor approved June 2025; most provisions effective January 1, 2026 (see Effective Dates).

Main purpose

Require Nevada Medicaid to cover screening for additional cancers (lung, colorectal, and prostate) to improve early detection and align Medicaid screening protections more closely with coverage available to commercially insured Nevadans.

Key provisions

  • Adds a new section to Chapter 422 of the Nevada Revised Statutes directing the Director of the Department of Health and Human Services (DHHS) to include under Medicaid coverage:
    • Screening for lung cancer;
    • Screening for colorectal cancer; and
    • Screening for prostate cancer.
  • Requires the Department to apply to the U.S. Secretary of Health and Human Services for any federal waiver or State Plan amendment necessary to obtain federal funding for the new coverage and to cooperate with the federal government in that process.
  • Conforming change to NRS 232.320 to list administration of this new provision among other DHHS responsibilities.
  • Effective dates:
    • Immediate effect for adoption of necessary regulations and preparatory administrative tasks; and
    • January 1, 2026 for other operative purposes.

Changes during the legislative process

  • Early versions and stakeholder materials sought explicit statutory protection for “all available evidence‑based methods” of colorectal screening (including at‑home multitarget stool DNA testing / mt‑sDNA like Cologuard).
  • Committee amendments and later reprints adjusted bill language. The enrolled (final) version requires coverage of colorectal cancer screening generally; some earlier, more specific language about all evidence‑based methods was proposed and debated but not retained in the final enrolled text.

Who is affected / likely impacts

  • Primary beneficiaries: Nevada Medicaid enrollees — expanded access to preventive screening for lung, colorectal, and prostate cancer.
  • Providers: primary care, radiology, gastroenterology, and cancer‑screening services may see changes in demand and billing/coverage processes.
  • State DHHS: responsible for implementing coverage, applying for federal approvals, and issuing regulations.
  • State budget: the bill has a fiscal impact on the State (federal match may offset some costs), but no specific dollar amounts are included in the bill text or summary.

Context and support

  • Advocates (Nevada Cancer Coalition, Fight Colorectal Cancer, Nevada Public Health Association, clinical providers and survivors) supported the bill to improve screening access—particularly for rural and underserved populations—and to reduce late‑stage cancer diagnoses.

Procedural highlights

  • Referred to Health & Human Services and Ways & Means committees; multiple amendments and two reprints considered.
  • Governor approval and chaptering occurred in mid‑2025; implementation steps and regulatory changes are expected to occur prior to the January 1, 2026 operative date.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.